Johnson & JohnsonvsArcus Biosciences

JNJ and RCUS stock compared: price, dividend, valuation and results, from SEC filings.

RCUS

Arcus Biosciences, Inc.

$16.07

Value $2.3B

-1.95%
RCUS's page

Johnson & Johnson (JNJ) has a market value of $665B and Arcus Biosciences (RCUS) $2.3B. Over the last year, with dividends, JNJ moved +41.4% and RCUS -19.6%. Dividend yield: JNJ 1.91%, RCUS none.

At a glance

The main figures of both. A bar only shows which number is larger, not which is better.

  • Market value

    JNJ$665B

    RCUS$2.3B

    JNJ is 287 times RCUS

  • Revenue, 12 months

    JNJ$99.3B

    RCUS$100M

    JNJ is 993 times RCUS

  • Net income, 12 months

    JNJ$16.1B

    RCUS-$453M

  • Operating margin

    JNJ–

    RCUS-475.0%

  • ROIC

    JNJ12.4%

    RCUS-64.4%

    76.8 points apart

  • P/E

    JNJ41.3

    RCUS–

  • Dividend yield

    JNJ1.9%

    RCUS0.0%

    1.9 points apart

  • 5-year return

    JNJ+94.3%

    RCUS-56.5%

    150.8 points apart

A fainter bar means a negative number. The 5-year return includes dividends.

The price over time

Both start at 100 at the beginning of the period, so the lines show how much each changed. With dividends means each dividend buys more shares.

JNJ+94.3%

RCUS-56.5%

10020020222023202420252026
Returns by period
PeriodJNJWith dividendsRCUSWith dividends
1 year since November 17, 2025+41.4%Price +38.3%-19.6%Price -19.6%
3 years since November 17, 2023+100.6%+26.1% a yearPrice +84.3%+10.9%+3.5% a yearPrice +10.9%
5 years since November 17, 2021+94.3%+14.2% a yearPrice +69.0%-56.5%-15.3% a yearPrice -56.5%

Each cell: the total return with dividends, its yearly rate, and the price change alone. Before taxes and costs. Past returns do not predict future ones.

Every figure

As on each company's page. A description, not a recommendation: no one figure says which is better.

JNJJohnson & JohnsonRCUSArcus Biosciences

Valuation

JNJRCUS
Valuation
Price$276.05$16.07
Market value$665B$2.3B
Enterprise value (EV)$693B–
P/E41.3–
P/E, 5-year median21.9–
P/B8.26.5
EV/EBIT39.1–
Free cash flow yield3.1%–

Results and growth

JNJRCUS
Results and growth
Revenue, 12 months$99.3B$100M
Net income, 12 months$16.1B-$453M
Free cash flow, 12 months$20.6B-$466M
Earnings per share, 12 months$6.59-$3.64
Revenue growth, year on year6.1%-4.3%
Revenue growth a year, past+2.7%over 5 years+25.9%over 5 years
EPS growth a year, past+14.9%over 5 years–

Margins and returns on capital

JNJRCUS
Margins and returns on capital
Gross margin67.6%–
Operating margin–-475.0%
Net margin16.2%-453.0%
ROIC12.4%-64.4%
ROE19.7%-93.9%

Balance sheet

JNJRCUS
Balance sheet
Cash$17.2B$630M
Total debt$44.7B–
Net debt / EBITDA1.1–
Interest cover18.0×-43.2×

Dividends and buybacks

JNJRCUS
Dividends and buybacks
Dividend yield1.9%–
Dividend per share, 12 months$5.28–
Dividend growth a year, past+5.3%over 5 years–
Buyback yield0.9%–
Shareholder yield2.8%–

Last 12 months from the latest 10-Q and 10-K. Value, P/E and yields at today's price. A dash means the figure does not exist or did not pass our checks.

Questions: JNJ or RCUS

Didn't find what you were looking for?

Ask us
Which is bigger, Johnson & Johnson or Arcus Biosciences?

By market value, Johnson & Johnson ($665B) is about 287.5 times Arcus Biosciences ($2.3B), at today's prices.

How did JNJ and RCUS stock do over the last 5 years?

Since November 17, 2021, JNJ's price moved +69.0% and RCUS's -56.5%. With dividends: JNJ +94.3% (+14.2% a year), RCUS -56.5% (-15.3% a year). Past returns do not predict future ones.

Which pays the higher dividend, JNJ or RCUS?

The dividend yield at today's price is 1.91% for Johnson & Johnson and none for Arcus Biosciences. Over the last twelve months they paid $5.28 and – per share.

Which has the higher profit margins, Johnson & Johnson or Arcus Biosciences?

Over the last twelve months, the net margin was 16.2% for Johnson & Johnson and -453.0% for Arcus Biosciences, and the operating margin – and -475.0%. Revenue was $99.3B and $100M.

Which is the better investment, Johnson & Johnson or Arcus Biosciences?

The page does not answer that and does not suggest buying or selling. It puts the two companies' numbers side by side, from their SEC filings, for you to read and form your own view. The decision depends on your goals and situation.

Other comparisons

With each of the two, and with the largest in its sector.

Related pages

The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.

Descriptive data from SEC filings and market prices.